Detalhe da pesquisa
1.
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Ann Hematol
; 103(2): 427-436, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38012435
2.
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Br J Haematol
; 196(3): 559-565, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-34636033
3.
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Hematol Oncol
; 39(3): 401-408, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33617659
4.
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib.
Ann Hematol
; 100(8): 2005-2014, 2021 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33388860
5.
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Acta Oncol
; 60(11): 1527-1533, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34499575
6.
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Ann Hematol
; 99(7): 1525-1530, 2020 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-32474619
7.
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia.
Eur J Haematol
; 105(3): 286-291, 2020 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-32365249
8.
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Hematol Oncol
; 37(3): 296-302, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-30892724
9.
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis.
Ann Hematol
; 98(8): 1933-1936, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31201513
10.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-31392461
11.
Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment.
Ann Hematol
; 97(5): 745-754, 2018 May.
Artigo
Inglês
| MEDLINE | ID: mdl-29468276
12.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
Ann Hematol
; 97(9): 1577-1580, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-29675611
13.
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Ann Hematol
; 97(1): 95-100, 2018 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-28971265
14.
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib.
Hematol Oncol
; 38(4): 607-610, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-32602167
15.
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Am J Hematol
; 95(10): E260-E263, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32557788
16.
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
Ann Hematol
; 98(11): 2609-2611, 2019 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-31529281
17.
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Haematologica
; 98(3): 399-403, 2013 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-22801965
18.
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Hematol Oncol
; 31(2): 103-9, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-22815278
19.
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Ann Hematol
; 92(2): 179-83, 2013 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-23053188
20.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
Am J Hematol
; 93(7): E159-E161, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29633312